Schnellzugriff

No journals followed

Browse journals

No saved papers

Feed Entdecken Trends Fragen Forschende

⌘K

Cannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials | Synapse

April 10, 2026Open Access

Cannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials

Key Points

To determine the efficacy of cannabidiol (CBD) for treating psychotic disorders through a meta-analysis of existing RCTs.
Conducted a meta-analysis of randomized controlled trials (RCTs) involving cannabidiol for psychosis.
Reviewed outcomes related to psychotic symptoms and tolerability of CBD.
Analyzed the quality and sample sizes of included studies.
CBD did not demonstrate a significant benefit for reducing psychotic symptoms.
Participants generally tolerated CBD well.
Emphasizes the need for larger, higher-quality trials to confirm findings.

Abstract

Despite the limited number of outcomes assessed at the current state of the evidence, CBD did not show a clear benefit for psychosis symptoms in RCTs but was generally well tolerated. Larger, high-quality trials are needed to reach more robust conclusions about CBD efficacy in these disorders.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Authors

M

Mattia Marchi

K

Karim Rachedi

A

Alessia Bof

Journals

Journal of Psychopharmacology

Actions

Institutions

University of Modena and Reggio Emilia

Azienda Sanitaria Unità Locale di Reggio Emilia

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Cite this study

Marchi et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d896566c1944d70ce07a61 — DOI: https://doi.org/10.1177/02698811261430501